Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3964 | 2015 |
DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2407 | 2015 |
Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 2056 | 2020 |
Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... New England Journal of Medicine 375 (5), 443-453, 2016 | 1756 | 2016 |
Genomic correlates of clinical outcome in advanced prostate cancer W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ... Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019 | 1201 | 2019 |
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ... Annals of Oncology 31 (11), 1491-1505, 2020 | 1081 | 2020 |
Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 717 | 2020 |
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ... Annals of Oncology 29 (9), 1895-1902, 2018 | 655 | 2018 |
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 630 | 2020 |
A decade of clinical development of PARP inhibitors in perspective J Mateo, CJ Lord, V Serra, A Tutt, J Balmaña, M Castroviejo-Bermejo, ... Annals of Oncology 30 (9), 1437-1447, 2019 | 608 | 2019 |
Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 416 | 2017 |
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ... The Journal of pathology 229 (3), 422-429, 2013 | 398 | 2013 |
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 288 | 2015 |
Delivering precision oncology to patients with cancer J Mateo, L Steuten, P Aftimos, F André, M Davies, E Garralda, J Geissler, ... Nature medicine 28 (4), 658-665, 2022 | 278 | 2022 |
Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 268 | 2020 |
DNA repair in prostate cancer: biology and clinical implications J Mateo, G Boysen, CE Barbieri, HE Bryant, E Castro, PS Nelson, ... European urology 71 (3), 417-425, 2017 | 240 | 2017 |
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 225 | 2018 |
Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of … D Lorente, J Mateo, AJ Templeton, Z Zafeiriou, D Bianchini, ... Annals of Oncology 26 (4), 750-755, 2015 | 217 | 2015 |
Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 211 | 2015 |
Sequencing of agents in castration-resistant prostate cancer D Lorente, J Mateo, R Perez-Lopez, JS de Bono, G Attard The Lancet Oncology 16 (6), e279-e292, 2015 | 191 | 2015 |